H
Heidi H. Gillenwater
Researcher at Onyx Pharmaceuticals
Publications - 27
Citations - 1218
Heidi H. Gillenwater is an academic researcher from Onyx Pharmaceuticals. The author has contributed to research in topics: Carfilzomib & Population. The author has an hindex of 13, co-authored 26 publications receiving 1042 citations. Previous affiliations of Heidi H. Gillenwater include University of Virginia.
Papers
More filters
Journal ArticleDOI
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos,Philippe Moreau,Antonio Palumbo,Douglas E. Joshua,Ludek Pour,Roman Hájek,Thierry Facon,Heinz Ludwig,Albert Oriol,Hartmut Goldschmidt,Laura Rosiñol,Jan Straub,Aleksandr Suvorov,Carla Araujo,Elena Rimashevskaya,Tomas Pika,Gianluca Gaidano,Katja Weisel,Vesselina Goranova-Marinova,Anthony P. Schwarer,Leonard Minuk,Tamas Masszi,Ievgenii Karamanesht,Massimo Offidani,Vania Hungria,Andrew Spencer,Robert Z. Orlowski,Heidi H. Gillenwater,Nehal Mohamed,Shibao Feng,Wee Joo Chng +30 more
TL;DR: The primary endpoint was progression-free survival in the intention-to-treat population and carfilzomib with dexamethasone could be considered in patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
Philippe Moreau,Douglas E. Joshua,W. J. Chng,Antonio Palumbo,H. Goldschmidt,Roman Hájek,Thierry Facon,Heinz Ludwig,Luděk Pour,Ruben Niesvizky,Albert Oriol,Laura Rosiñol,Aleksandr Suvorov,Gianluca Gaidano,Tomas Pika,Katja Weisel,Vesselina Goranova-Marinova,Heidi H. Gillenwater,Nehal Mohamed,Sanjay K. Aggarwal,Shibao Feng,Meletios A. Dimopoulos +21 more
TL;DR: Subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment found outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number ofPrior therapy lines or prior exposure to bortsomib or lenalidomide.
Journal ArticleDOI
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.
Thomas A. Hensing,Nasser H. Hanna,Heidi H. Gillenwater,M. Gabriella Camboni,Cecilia Allievi,Mark A. Socinski +5 more
TL;DR: The toxicity profile of BBR 3464 in this phase II trial is consistent with the phase I experience, and the lack of activity in either patient subgroup does not support further evaluation of this drug as a single agent in this disease.
Journal ArticleDOI
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W. J. Chng,W. J. Chng,H. Goldschmidt,Meletios A. Dimopoulos,Philippe Moreau,Douglas E. Joshua,Antonio Palumbo,Thierry Facon,Heinz Ludwig,Luděk Pour,Ruben Niesvizky,Albert Oriol,Laura Rosiñol,Aleksandr Suvorov,Gianluca Gaidano,Tomas Pika,Katja Weisel,Goranova-Marinova,Heidi H. Gillenwater,Nehal Mohamed,Shibao Feng,Sanjay K. Aggarwal,Roman Hájek +22 more
TL;DR: A preplanned subgroup analysis of ENDEAVOR found that Kd was superior to Vd in relapsed or refractory MM, regardless of cytogenetic risk.
Journal ArticleDOI
Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer
David R. Jones,Christopher A. Moskaluk,Heidi H. Gillenwater,Gina R. Petroni,Sandra G. Burks,Jennifer Philips,Patrice K. Rehm,Juan M Olazagasti,Benjamin D. Kozower,Yongde Bao +9 more
TL;DR: Induction bortezomib and vorinostat therapy followed by surgery in patients with operable NSCLC is feasible and relative gene-expression studies suggest new targets and cell-signaling pathways that may be important in modulating this combined therapy.